ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.
Fuster
V
V
Rydén
L E
LE
Asinger
R W
RW
Cannom
D S
DS
Crijns
H J
HJ
Frye
R L
RL
Halperin
J L
JL
Kay
G N
GN
Klein
W W
WW
Lévy
S
S
McNamara
R L
RL
Prystowsky
E N
EN
Wann
L S
LS
Wyse
D G
DG
Gibbons
R J
RJ
Antman
E M
EM
Alpert
J S
JS
Faxon
D P
DP
Fuster
V
V
Gregoratos
G
G
Hiratzka
L F
LF
Jacobs
A K
AK
Russell
R O
RO
Smith
S C
SC
Klein
W W
WW
Alonso-Garcia
A
A
Blomström-Lundqvist
C
C
De Backer
G
G
Flather
M
M
Hradec
J
J
Oto
A
A
Parkhomenko
A
A
Silber
S
S
Torbicki
A
A
D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006328:Cardiac Catheterization; D017115:Catheter Ablation; D004554:Electric Countershock; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics; D006801:Humans; D019934:International Normalized Ratio; D011788:Quality of Life; D018570:Risk Assessment; D013923:Thromboembolism / Q000150:complications / Q000503:physiopathology; D014859:Warfarin / Q000627:therapeutic use; D014927:Wolff-Parkinson-White Syndrome / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D014859:Warfarin